Trial reportThe Journal of clinical investigation1997
The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics.
Trial report in The Journal of clinical investigation, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 176 citations in OpenAlex.
- Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.The Cochrane database of systematic reviews · 2021Pooled it
- Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.The Cochrane database of systematic reviews · 2018Pooled it
- Helminth therapy (worms) for allergic rhinitis.The Cochrane database of systematic reviews · 2012Pooled it
- Structural and Functional Insights Into IgE Receptor Interactions and Disruptive Inhibition.Immunological reviews · 2025Review
- Biologics in Asthma: A Molecular Perspective to Precision Medicine.Frontiers in pharmacology · 2021Review
- Past, present, and future of anti-IgE biologics.Allergy · 2020Review
- Generation of IgE-specific cytotoxic T lymphocytes as a novel immunotherapeutic approach for the treatment of allergic asthma.Singapore medical journal · 2020Article
- Half-life of IgE in serum and skin: Consequences for anti-IgE therapy in patients with allergic disease.The Journal of allergy and clinical immunology · 2017Review
- From IgE to Omalizumab.Journal of immunology (Baltimore, Md. : 1950) · 2016Review
- New strategies with anti-IgE in allergic diseases.The World Allergy Organization journal · 2014Review
- Developing therapies for peanut allergy.International archives of allergy and immunology · 2014Review
- Mechanisms of asthma and implications for its prevention and treatment: a personal journey.Allergy, asthma & immunology research · 2013Review
- What Taiwan contributes to the world of allergy and clinical immunology?Asia Pacific allergy · 2013Review
- Asthma: beyond corticosteroid treatment.Archives of medical science : AMS · 2013Article
- Does this patient have atopic asthma?Clinical medicine (London, England) · 2011Review
- Monoclonal antibodies for the treatment of severe asthma.Current allergy and asthma reports · 2011Review
- A peptide binding to dimerized translationally controlled tumor protein modulates allergic reactions.Journal of molecular medicine (Berlin, Germany) · 2011Article
- A brief history of asthma and its mechanisms to modern concepts of disease pathogenesis.Allergy, asthma & immunology research · 2010Article
- Immunotherapy for allergies and asthma: present and future.Current opinion in pharmacology · 2010Review
- Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice.The Journal of clinical investigation · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CGP 51901 is a non-anaphylactogenic mouse/human chimeric anti-human IgE antibody that binds to free IgE and surface IgE of IgE-expressing B cells but not to IgE bound to high affinity IgE receptors (Fc epsilonR1) on mast cells and basophils or low affinity IgE receptors (Fc epsilonR2) on other cells. A phase 1 double-blind, placebo-controlled, single dose study with doses of 3, 10, 30, and 100 mg of CGP 51901 was conducted in 33 pollen-sensitive subjects who had raised levels of serum IgE and received either intravenous CGP 51901 or placebo. The administration of CGP 51901 was well tolerated and resulted in a decrease of serum free IgE levels in a dose-dependent manner, with suppression after 100 mg of CGP 51901 reaching > 96%. Time of recovery to 50% of baseline IgE correlated with the dose of administered antibody and ranged from a mean of 1.3 d for the 3 mg to 39 d for the 100 mg dose. Total IgE, comprised of free and complexed IgE, increased as stored and newly synthesized IgE bound to CGP 51901. Complexed IgE was eliminated at a rate comparable with the terminal half-life of free CGP 51901 (11-13 d at all doses). Only one subject showed a weak antibody response against CGP 51901. We conclude that the use of anti-human IgE antibody is safe and effective in reducing serum IgE levels in atopic individuals and provides a potential therapeutic approach to the treatment of atopic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.